Form 483 Field Guide: FDA Follow-Up for Life Sciences Manufacturers

October 15, 2026 | 12:00PM–1:30PM ET | Live Webinar

Register Now Cracking the New National Drug Code Format September 24, 2026, 2:00-3:30PM ET | Live Webinar
BUY NOW FDA and Medical Product Oversight: Assessing Recent Changes Recorded June 25, 2025 | On-Demand Webinar

Overview

Form 483 observations remain a critical focus for drug, biologic, and medical device manufacturers preparing for FDA inspections and addressing compliance concerns. This webinar will explore current 483 trends, response strategies, and common pitfalls, along with insights from FDA’s recent draft guidance on responding to Form 483 observations for human and animal drug and biologic manufacturers. Join our panel of experts for practical guidance on developing effective 483 responses and strengthening inspection readiness.

$149

Members

$249

Non-Members

Speakers

Lisa El-Shall
Read Bio
Senior Director, Pharmaceutical and Device Consulting Services, EAS Consulting Group

Dennis Gucciardo
Read Bio
Partner, Morgan, Lewis & Bockius LLP

Sonia W. Nath
Read Bio
Partner and Chair, Life Sciences and Healthcare Regulatory Practice, Cooley LLP

FDLI applies for CLE credits in Ohio and Virginia. These CLE approvals also may be honored by other states. The CLE credits will be posted as they are granted and registrants can request to be notified when approval is received.